sabato, 28 novembre 2020
7 Gennaio 2019

FDA Approves Dasatinib for Pediatric Ph+ ALL

January 2, 2019 – The FDA has approved dasatinib tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The approval was based on findings from a single cohort of the phase II CA180-372 trial (NCT01460160), which demonstrated a 3-year event-free survival (EFS) binary rate of 64.1% (95% CI, 52.4%-74.7%) in 78 … (leggi tutto)